Abiopharma

🔍 Susan Lior (Executive)

Company: Cerebras Systems Inc. (CBRS)

Report Date: 2026-08-19

Detailed Transactions and Holdings:

• Sold 902,235 shares of Class A Common Stock (Direct)
  Date: 2026-08-19 | Code: J | equity_swap_involved: false | shares_owned_after: 8,295,180.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2
• Acquired 46,422 shares of Class A Common Stock (Direct)
  Date: 2026-08-19 | Code: J | equity_swap_involved: false | shares_owned_after: 244,206.00 | transaction_form_type: 4 | Footnotes: F3, F3
• Acquired 46,780 shares of Class A Common Stock (Direct)
  Date: 2026-08-19 | Code: J | equity_swap_involved: false | shares_owned_after: 207,571.00 | transaction_form_type: 4 | Footnotes: F3, F3, F4

Footnotes:

• F1: Represents a pro-rata, in-kind distribution by the Eclipse Entities (as defined below) to its partners, for no additional consideration (the "Distribution").
• F2: Following the distribution, consists of (i) 493,021 shares of Class A common stock held by Eclipse Continuity Fund I, L.P. ("Eclipse Continuity Fund"); (ii) 4,033,856 shares of Class A common stock held by Eclipse SPV II, L.P. ("Eclipse SPV II"); (iii) 369,527 shares of Class A common stock held by Eclipse SPV XIII, L.P. ("Eclipse SPV XIII"); and (iv) 3,398,776 shares of Class A common stock held by Eclipse Ventures Fund I, L.P. ("Eclipse Fund," and together with Eclipse Continuity Fund, Eclipse SPV II, and Eclipse SPV XIII, "Eclipse Entities"). The Reporting Person is the sole managing member of the general partner of each of the Eclipse Entities and may be deemed to have voting, investment, and dispositive power with respect to the shares held by such entities.
• F3: The shares were obtained pursuant to a pro-rata, in-kind distribution from the Eclipse Entities, for no additional consideration.
• F4: The shares are held directly by an estate-planning vehicle which is controlled by the Reporting Person.